Full Text View
Tabular View
No Study Results Posted
Related Studies
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
This study is ongoing, but not recruiting participants.
Study NCT00055913   Information provided by National Cancer Institute (NCI)
First Received: March 6, 2003   Last Updated: March 28, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Head and Neck Cancer
Additional conditions recognized in this trial
Head and Neck Neoplasms
More general conditions related to this trial
Neoplasms
Neoplasms by Site
Interventions listed in this trial
bevacizumab
erlotinib hydrochloride
Additional drug interventions recognized in this trial
Erlotinib
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Enzyme Inhibitors
Growth Inhibitors
Growth Substances
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
University of Chicago
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services